#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Alagille syndrome Chordoma Neurodermatitis Neuroendocrine carcinoma of the skin Extra-osseous Ewing's sarcoma recurrent Idiopathic intracranial hypertension Kidney transplant rejection Osteomyelitis Gestational trophoblastic tumour Retinopathy proliferative Pyruvate kinase deficiency anaemia Chronic lymphocytic leukaemia refractory Epilepsy with myoclonic-atonic seizures Congenital growth hormone deficiency Cutaneous T-cell lymphoma refractory More trials…

    Learn about Rare Diseases

    Haemophilia A with anti factor VIII – Trials in Disease Retinoblastoma – Life with Disease Haemophilia A without inhibitors – Life with Disease Angiosarcoma – Basic Information Von Willebrand’s disease – Life with Disease Ewing’s sarcoma recurrent – Life with Disease Proteus syndrome – Treatment Lymphangioma Pemphigus – Life with Disease Chondrosarcoma metastatic – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Serpina1(Human)-Aav8-1 Sodium Cromoglicate Pramipexole Levofloxacin Hemihydrate Camonsertib Etidronate Disodium Glyceryl Trinitrate Cdr132L Onfekafusp Alfa Mebufotenin Mps-213 Tiaprofenic Acid UDONITRECTAG Prednisolone Sodium Phosphate Metformin Tiotropium Bromide Monohydrate Ianalumab Bio89-100 Piritramide Gilteritinib More therapies…

    Learn about Your Condition

    Atopic keratoconjunctivitis Thrombocytopenia Breast cancer male Pulmonary fibrosis Epstein-Barr virus infection Hydrocele Skin wrinkling Prodromal Alzheimer's disease Partial seizures Heart disease congenital Type IIa hyperlipidaemia Irritable bowel syndrome Breast angiosarcoma Angiosarcoma metastatic Latent tuberculosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Prostate cancer metastatic

  • Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Enzalutamide
    • Pembrolizumab
    Austria Bulgaria Czechia France Germany Hungary +5

  • Study Comparing Docetaxel, Darolutamide, and ADT for Patients with Metastatic Hormone-Sensitive Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Buserelin Acetate
    • Goserelin Acetate
    • Relugolix
    Austria Germany

  • Study on Darolutamide and Androgen Deprivation Therapy for Men with Metastatic Hormone-Sensitive Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • Darolutamide
    Latvia Lithuania Spain

  • Study of Nivolumab, Ipilimumab, or Cabazitaxel for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Cabazitaxel
    • Ipilimumab
    • Nivolumab
    Germany

  • Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Enzalutamide
    • Talazoparib
    Belgium Czechia Finland France Germany Hungary +6
Previous Page
1 … 6 7 8

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!